Néovacs: August drawdown on its €2.25M financing line not realized
Biopharmaceutical company Néovacs informed the market of the status of its dilutive financing line. The monthly drawdown scheduled for August 2026 was not executed and the company states it did not receive the corresponding funds.
A scheduled monthly drawdown of €250k was not executed
Néovacs (Euronext Growth Paris: ALNEV) announced on August 25, 2026 that the drawdown planned for August, under its €2.25M financing line, was not realized.
On March 24, 2026, the company had announced the implementation of a scheduled drawdown calendar of a tranche of €250k (€245k net) every month, starting from April 2026 through December 2026 inclusive, for a total cumulative amount of €2.25M.
To date, the drawdown scheduled for August 17 has not been executed and the Company states it has not received the corresponding funds. The tracking table of drawdowns and conversions is available on the Company's website.
A dilutive financing mechanism for which Néovacs reiterates the risks
The company specifies that it has implemented financing in the form of OCEANE-BSA with Hanover Square Investments 1, as well as ORA financing which have all been transferred to a trust responsible for their equitization.
Néovacs reiterates that shares resulting from the conversion or exercise of these securities are generally sold on the market at very short notice, which may create downward pressure on the share price. It indicates that shareholders may suffer a loss of their invested capital as well as dilution linked to the number of securities issued.
The Company adds that this mechanism is not the first one it has implemented and that it will keep the market informed of developments in the situation.
